Table 4 Mammaprint-trained results stratified by other test results, trinary classification.

From: Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

 

Mammaprint-trained first

 

Mammaprint-trained low risk

Mammaprint-trained high risk

 

HR (95% CI)

DMFS (95% CI)

P* (N)

HR (95% CI)

DMFS (95% CI)

P (N)

All cases

REF

86.9

(85.1–88.4)

<0.001

(2180)

2.64

(2.22–3.14)

70.7

(67.6–73.6)

<0.001

(1104)

N-Ch−

REF

93.5

(90.5–95.6)

<0.001

(599)

4.23

(2.72–6.56)

78.2

(73.0–82.5)

<0.001

(371)

N+Ch−

REF

85.9

(83.1–88.3)

<0.001

(896)

3.34

(2.56–4.36)

62.4

(56.5–67.7)

<0.001

(351)

Ch+

REF

82.3

(78.8–85.3)

<0.001

(681)

1.86

(1.41–2.46)

71.2

(65.8–75.9)

<0.001

(379)

 

Oncotype-trained low

Oncotype-trained Int

Oncotype-trained high

Oncotype-trained low

Oncotype-trained Int

Oncotype-trained high

HR

DMFS

P*

HR

DMFS

P

HR

DMFS

P

HR

DMFS

P*

HR

DMFS

P

HR

DMFS

P

All cases

REF

89.1

(87.1–90.8)

<0.001

(1483)

1.74

(1.33–2.28)

83.2

(79.6–86.1)

<0.001

(645)

3.22

(1.82–5.69)

70.4

(53.7–82.1)

<0.001

(52)

REF

72.1

(60.9–80.6)

0.031

(124)

1.10

(0.72–1.68)

73.2

(68.8–77.2)

0.668

(528)

1.47

(0.97–2.24)

67.1

(62.2–71.6)

0.072

(452)

N−Ch−

REF

93.8

(90.0–96.2)

0.485

(407)

1.35

(0.62–2.92)

92.2

(85.6–95.8)

0.452

(174)

NA

100

NA

(18)

REF

80.8

(62.8–90.7)

0.196

(51)

1.12

(0.49–2.56)

80.8

(73.2–86.4)

0.784

(175)

1.68

(0.74–3.80)

74.0

(65.0–81.0)

0.212

(145)

N+Ch−

REF

87.7

(84.4–90.3)

<0.001

(639)

1.49

(0.98–2.29)

84.2

(78.2–88.7)

0.064

(237)

5.14

(2.46–10.7)

54.2

(28.0–74.5)

<0.001

(20)

REF

67.6

(48.0–81.2)

0.047

(44)

1.22

(0.63–2.35)

66.9

(58.3–74.1)

0.552

(166)

1.83

(0.96–3.49)

55.3

(46.0–63.6)

0.067

(141)

Ch+

REF

86.8

(82.6–90.0)

<0.001

(434)

2.05

(1.38–3.06)

75.8

(69.1–81.2)

<0.001

(233)

3.52

(1.40–8.86)

61.1

(29.8–81.9)

0.007

(14)

REF

64.2

(37.6–81.8)

0.903

(29)

0.85

(0.40–1.81)

71.2

(63.0–77.9)

0.676

(185)

0.90

(0.42–1.92)

71.9

(63.8–78.4)

0.792

(165)

 

Prosigna-trained low

Prosigna-trained Int

Prosigna-trained high

Prosigna-trained low

Prosigna-trained Int

Prosigna-trained high

HR

DMFS

P*

HR

DMFS

P

HR

DMFS

P

HR

DMFS

P*

HR

DMFS

P

HR

DMFS

P

All cases

REF

92.2

(89.8–94.0)

<0.001

(814)

1.77

(1.27–2.46)

86.1

(83.3–88.5)

0.001

(944)

3.01

(2.11–4.28)

78.1

(73.0–82.3)

<0.001

(422)

REF

90.0

(47.3–98.5)

0.006

(12)

2.17

(0.30–15.8)

79.4

(72.6–84.7)

0.446

(211)

3.57

(0.50–25.5)

68.4

(64.9–71.7)

0.204

(881)

N−Ch−

REF

96.6

(91.8–98.6)

0.069

(217)

2.24

(0.80–6.28)

93.1

(88.1–96.0)

0.126

(249)

3.37

(1.15–9.86)

89.6

(80.6-94.5)

0.027

(133)

REF

100

0.222

(3)

NA

83.8

(70.2-91.5)

NA

(72)

NA

76.5

(70.6–81.4)

NA

(296)

N+Ch−

REF

90.0

(85.7–93.1)

<0.001

(315)

1.28

(0.79–2.06)

86.6

(82.2–90.0)

0.315

(415)

2.65

(1.59–4.42)

75.7

(66.8–82.5)

<0.001

(166)

REF

100

0.002

(3)

NA

83.6

(70.7–91.1)

NA

(61)

NA

57.4

(50.8–63.5)

NA

(287)

Ch+

REF

91.1

(86.5–94.2)

<0.001

(281)

2.42

(1.45–4.03)

79.3

(73.3–84.2)

0.001

(278)

3.91

(2.26–6.79)

69.0

(58.8–77.2)

<0.001

(122)

REF

75.0

(12.8–96.1)

0.951

(6)

1.38

(0.19–10.3)

72.7

(60.8–81.5)

0.752

(78)

1.37

(0.19–9.83)

70.9 (64.7–76.2)

0.756

(295)

  1. HR = hazard ratio, 95%CI = 95% confidence interval. P* = p value of log-rank test to compare survival distributions. REF = reference group. P = p value of Wald test for comparison versus reference (low risk) group. DMFS = distant metastasis free survival at 10 years (see text). (N) = number of cases in subgroups. All cases = all ER+ve/HER2-ve cases. N−Ch− = node negative cases treated without chemotherapy. N+Ch− = Node positive cases treated without chemotherapy. Ch+ = cases treated with chemotherapy (node negative and node positive combined). Int = intermediate.
Back to article page